Group 1 - The stock price of *ST Bio (000504) closed at 11.91 yuan, down 5.02%, with a turnover rate of 1.1% and a trading volume of 36,100 shares, amounting to 43.0165 million yuan [1] - The net outflow of main funds was 12.0255 million yuan, accounting for 27.96% of the transaction amount, with large orders showing a net outflow of 12.9843 million yuan, which is 30.18% of the transaction amount [1] - The latest financial report for *ST Bio shows total operating revenue of 22.4536 million yuan, a year-on-year decrease of 13.55%, while net profit attributable to shareholders was 2.2186 million yuan, an increase of 19.92% [1] Group 2 - Nanhua Biological Pharmaceutical Co., Ltd. was established in 1991 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 3,300.23098 million yuan and paid-in capital of 3,115.73901 million yuan [2] - The company has made investments in 11 enterprises and participated in 7 bidding projects, holding 46 trademark registrations and 4 patents [2]

消息面上，*ST生物发布公告称，公司正在筹划以现金方式收购湖南慧泽生物医药科技有限公司51%股 权。在披露重组公告前，*ST生物连续两个交易日涨停。 北京商报讯（记者 丁宁）8月12日，*ST生物（000504）开盘跌停，报跌停价11.91元/股，跌幅为 5.02%。 ...

Core Viewpoint - The company *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will result in Huize becoming a subsidiary of *ST Bio, indicating a significant asset restructuring [2][6]. Group 1: Acquisition Details - The acquisition of Huize Medical, a professional CRO company focused on drug research and clinical evaluation, is expected to enhance *ST Bio's capabilities in the biopharmaceutical sector [5][6]. - Huize Medical generates over 85% of its revenue from clinical evaluation services and has established long-term partnerships with over 300 pharmaceutical companies and research institutions [5]. Group 2: Strategic Benefits - The acquisition is anticipated to extend *ST Bio's biopharmaceutical business, improving its profitability and risk resilience [6]. - The integration of drug research and clinical evaluation services is expected to enhance operational efficiency and create strong synergies [6]. Group 3: Financial Performance - *ST Bio has projected a revenue of 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13% [7]. - The company expects a net loss attributable to shareholders of 3.5 million to 5 million yuan, an improvement from a loss of 8.39 million yuan in the same period last year [7]. Group 4: Stock Performance - Following a period of stock price decline, *ST Bio's shares were subject to delisting risk warnings starting April 30, 2025, with the stock price dropping to a low of 5.43 yuan per share on April 28 [9]. - Recently, the stock price has rebounded, closing at 12.54 yuan per share as of August 11 [10].

Group 1 - The core point of the article is that *ST Bio (000504) is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will result in Huize becoming a subsidiary of the company, indicating a significant asset restructuring [2] - Huize is a professional CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services, and has established long-term partnerships with over 300 pharmaceutical companies and research institutions [5] - The acquisition is expected to enhance *ST Bio's biopharmaceutical business, improve profitability, and increase the company's risk resistance, while also creating synergies through asset integration in clinical research and drug development [5][6] Group 2 - The transaction is anticipated to strengthen the overall growth and profitability of *ST Bio, aligning with the company's strategic development needs and fostering long-term sustainable growth [6] - Following the acquisition, *ST Bio's biopharmaceutical segment will include drug research and clinical evaluation services, enhancing its competitive edge [6] - *ST Bio has previously disclosed a performance forecast, expecting revenue between 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13% [6]

Core Viewpoint - *ST生物 is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements. This transaction is expected to constitute a significant asset restructuring as per the regulations [1] Group 1: Company Overview - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, providing services such as pharmaceutical research, clinical trials, and data management statistical analysis [1] - Prior to the acquisition, *ST生物 primarily engaged in two business segments: "biomedical" and "energy conservation and environmental protection," along with the production and sales of other biomedical-related products [1] Group 2: Strategic Intent - The acquisition aims to extend the biomedical segment of *ST生物, enhancing the profitability of its main business and improving its risk resistance capabilities [1] - There is a strong correlation between cell clinical transformation research and drug development, and the asset integration is expected to improve operational efficiency and create significant synergies [1]

Core Viewpoint - The company *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements. This transaction is expected to constitute a major asset restructuring as defined by regulations [1] Group 1: Company Overview - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, offering services such as pharmaceutical research, clinical trials, and data management statistical analysis [1] - Prior to the acquisition, the company primarily engaged in two business segments: "biomedical" and "energy conservation and environmental protection," along with the production and sales of related biomedical products [1] Group 2: Strategic Intent - The acquisition aims to extend the company's biomedical business, enhancing its profitability and risk resistance [1] - There is a strong correlation between cell clinical transformation research and drug development, and the asset integration is expected to improve operational efficiency and create significant synergies [1]

Group 1 - The Ministry of Finance and the State Taxation Administration have released a draft for public consultation regarding the implementation regulations of the Value-Added Tax Law, which clarifies definitions and taxpayer categories [1] - The Central Securities Depository Company has simplified the account opening process for foreign central bank institutions by eliminating the requirement for a signed commitment letter [1][7] - The China Association of Automobile Manufacturers reported that from January to July, sales of new energy vehicles reached 8.22 million units, a year-on-year increase of 38.5% [4] Group 2 - Trust companies have begun receiving the latest regulatory ratings for 2024, with the highest known rating being level 2, indicating a focus on risk management and operational stability [5] - Shanghai Clearing House has also simplified the account opening materials for foreign institutions, enhancing the investment environment in the bond market [7] - Several companies are making significant moves, such as *ST Bio planning to acquire a 51% stake in Huize Pharmaceutical, and Chang'an Automobile's executives planning to increase their shareholdings [8]

Group 1 - The core point of the article is that *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd., which will become a subsidiary after the transaction, indicating a significant asset restructuring [1] - Huize Biomedical is a specialized CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services and established partnerships with over 300 pharmaceutical companies and research institutions [1] - The acquisition is expected to enhance *ST Bio's profitability and risk resistance by extending its biopharmaceutical business and improving operational efficiency through asset integration [1] Group 2 - The transaction is anticipated to strengthen the overall growth and profitability of *ST Bio, fostering core competitiveness in the new production capacity system and supporting long-term sustainable development [2] - Following the acquisition, *ST Bio's biopharmaceutical segment will include drug research and clinical evaluation services, which will enhance the company's competitive edge and align with shareholder interests [2] - *ST Bio previously forecasted a revenue of 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13%, with a projected net loss of 3.5 million to 5 million yuan [2]

Core Viewpoint - *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements [1] Group 1: Acquisition Details - The acquisition aims to enhance the company's industrial chain layout by leveraging Huize's technological accumulation and customer resources in drug research and clinical evaluation [1] - Following the announcement, *ST Bio has experienced two consecutive trading days of limit-up gains [1]

格隆汇8月11日丨*ST生物（维权）(000504.SZ)公布，公司正在筹划以现金方式收购湖南慧泽生物医药 科技有限公司(简称"慧泽医药"或"标的公司")51%股权，本次交易完成后，慧泽医药将成为公司控股子 公司并纳入合并报表范围。 ...